The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | ZENITH20-4: efficacy & safety of poziotinib in treatment-naïve NSCLC with HER2 exon 20 mutations
Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, presents the results from the ZENITH20-4 study (NCT03318939), a multinational Phase II study evaluating the efficacy and safety of poziotinib, a potent tyrosine kinase inhibitor, in newly diagnosed patients with non-small cell lung cancer (NSCLC) and HER2 exon 20 insertion mutations. In this study, poziotinib demonstrated clinically meaningful efficacy in newly diagnosed NSCLC patients with HER2 exon 20 mutations with a safety profile similar to other second generation tyrosine kinase inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
